Файл: Монография Томск.docx

Литература

1. 
   Canfield J., Totary-Jain H. 40 Years of Percutaneous Coronary Intervention: History and Future Directions // J Pers Med. – 2018.
   

2. 
   Puel J., Joffre F., Rousseau H. et al. Self-expanding coronary endoprosthesis in the prevention of restenosis following transluminal angioplasty. Preliminary clinical study [in French] // Arch Mal Coeur Vaiss. – 1987. – Vol. 80 (8). – P. 1311–1312.
   

3. 
   Sigwart U., Puel J., Mirkovitch V., Joffre F., Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty // N. Engl. J. Med. – 1987. – Vol. 316. – P. 701–706. – doi: 10.1056/NEJM198703193161201.
   
4. 
   Bertrand M.E. History and evolution of coronary stenting // Medicographia. – 2016. – Vol. 38 (3). – P. 328–334.
   
5. 
   Fischman D.L., Leon M.B., Baim D.S. et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators // N. Engl. J. Med. – 1994. – Vol. 331. – P. 496–501. – doi: 10.1056/NEJM199408253310802.
   
6. 
   Serruys P.W., Strauss B.H., Beatt K.J. et al. Angiographic follow- up after placement of a self-expanding coronary-artery stent // N. Engl. J. Med. – 1991. – Vol. 324. – P. 13–17. – doi: 10.1056/ NEJM199101033240103.
   
7. 
   Hoffmann R., Mintz G.S., Dussaillant G.R. et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study // Circulation. – 1996. – Vol. 94. – P. 1247– 1254. – doi: 10.1161/01.CIR.94.6.1247.
   
8. 
   Moses J.W., Leon M.B., Popma J.J. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery // N. Engl. J. Med. – 2003. – Vol. 349. – P. 1315– 1323. – doi: 10.1056/NEJMoa035071.
   
9. 
   Weisz G., Leon M.B., Holmes D.R. et al. Two-year outcomes after sirolimus-eluting stent implantation: Results from the sirolimus- eluting stent in de novo native coronary lesions (sirius) trial // J. Am. Coll. Cardiol. – 2006. – Vol. 47. – P. 1350–1355. – doi: 10.1016/j.jacc.2005.11.077.
   
10. 
    Weisz G., Leon M.B., Holmes D.R. et al. Five-year follow-up after sirolimus-eluting stent implantation results of the sirius (sirolimus-eluting stent in de-novo native coronary lesions) trial
    

11. 
    Stone G.W., Ellis S.G., Cox D.A. et al. A polymer-based,
    

12. 
    Stone G.W., Moses J.W., Ellis S.G. et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents // N. Engl. J. Med. – 2007. – Vol. 356. – P. 998–1008. – doi: 10.1056/ NEJMoa067193.
    
13. 
    Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis // Lancet. – 2007. –Vol. 370. – P. 937–948. – doi: 10.1016/S0140–6736(07)61444–5.
    
14. 
    Otsuka F., Finn A.V., Yazdani S.K. et al. The importance of the endothelium in atherothrombosis and coronary stenting // Nat. Rev. Cardiol. – 2012. – Vol. 9. – P. 439–453. – doi: 10.1038/ nrcardio.2012.64.
    
15. 
    Tomey M., Mehran R. Dual antiplatelet therapy dilemmas: Duration and choice of antiplatelets in acute coronary syndromes
    

16. 
    Toyota T., Shiomi H., Morimoto T., Kimura T. Meta-analysis of long-term clinical outcomes of everolimus-eluting stents // Am. J. Cardiol. – 2015. – Vol. 116. – P. 187–194. – doi: 10.1016/j. amjcard.2015.03.059.
    
17. 
    Palmerini T., Benedetto U., Biondi-Zoccai G. et al. Long- term safety of drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis // J. Am. Coll. Cardiol. – 2015. – Vol. 65. – P. 2496–2507. – doi: 10.1016/j. jacc.2015.04.017.
    
18. 
    Bonaa K.H., Mannsverk J., Wiseth R. et al. Drug-eluting or bare- metal stents for coronary artery disease // N. Engl. J. Med. – 2016.
    

19. 
    Jensen L.O., Thayssen P., Christiansen E.H. et al. Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-year results from SORT OUT IV // J. Am. Coll. Cardiol. – 2016. – Vol. 67. – P. 751–762. – doi: 10.1016/j.jacc.2015.11.051.
    

20. 
    Piccolo R., Stefanini G.G., Franzone A. et al. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: A meta-analysis // Circ. Cardiovasc. Interv. – 2015. – Vol. 8. – e002223. – doi: 10.1161/ CIRCINTERVENTIONS.114.002223.
    
21. 
    Sorrentino S., Giustino G., Mehran R., Kini A.S. et al. Everolimus- eluting bioresorbable scaffolds versus everolimus-eluting metallic stents // J. Am. Coll. Cardiol. – 2017. – Vol. 69. – P. 3055–3066.
    
22. 
    Montone R.A., Niccoli G., De Marco F., Minelli S. et al. Temporal trends in adverse events after everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent implantation: A meta-analysis of randomized controlled trials // Circulation. – 2017. – Vol. 135. – P. 2145–2154.
    
23. 
    ESC/EACTS Guidelines on myocardial revascularization
    

ПЕРВИЧНОЕ ЧКВ ПРИ STEMI

1. Критерии коронарной реперфузии при первичном ЧКВ

• 
  TIMI 0 – отсутствие антеградного кровотока;
  
• 
  TIMI 1 – частичное просачивание контраста ниже точ- ки окклюзии;
  
• 
  TIMI 2 – контрастирование сосуда с замедленным на- полнением дистального русла;
  
• 
  TIMI 3 – нормальный кровоток.
  

2. Основные термины и целевые временные интервалы при певичном ЧКВ